The Edit. 11.03.2025.
Forging the Future of Finance.
Week of November 3rd, 2025
Market Update
FirstSun will acquire First Foundation in an all-stock deal, forming a bank with about $17 billion in total assets.
Why it matters: This deal highlights ongoing small-bank M&A as firms seek efficiency, scale, and stability amid a challenging interest-rate environment. It highlights pressure on community lenders to scale up amid tighter regulations, slowing loan growth, and margin compression.
OpenAI is preparing for an initial public offering (IPO) that could value the company at up to US$1 trillion.
Why it matters: A $1 trillion valuation would make OpenAI one of the largest IPOs in history, cementing AI as a central driver of global markets. It signals OpenAI’s evolution into a full-scale tech powerhouse and is likely to intensify competition and capital flows across the AI industry.
The U.S. government partnered with Westinghouse Electric Company, along with Brookfield and Cameco, in a deal worth around $80 billion to build new nuclear reactors across the country using Westinghouse technology.
Why it matters: The partnership boosts U.S. energy security and climate goals by expanding reliable, carbon-free power generation to meet rising electricity demand from AI and industry. It also revitalizes the domestic nuclear sector, creating jobs, strengthening supply chains, and reinforcing America’s global leadership in advanced nuclear technology.
Deal of the Week
Household Names Unite for a $48.7 Billion Consumer Health Shakeup
Kimberly-Clark Acquires Tylenol Maker Kenvue in USD $48.7B Deal
On November 3, 2025, Kimberly-Clark (NYSE: KMB) announced its acquisition of Kenvue, the parent company of Tylenol, in a deal valued at USD $48.7 billion. This strategic merger brings together iconic brands such as Huggies, Kleenex, Band-Aid, Aveeno, Johnson’s and Neutrogena under one consumer health brand. The cash-and-stock transaction will see Kimberly-Clark shareholders own approximately 54% of the combined company, while Kenvue shareholders hold the remaining 46%
Kenvue was spun off from Johnson & Johnson in 2023 to become a standalone consumer health business but has faced a turbulent start with weak sales, legal challenges around talc products and controversial claims surrounding Tylenol’s safety. Kimberly-Clark’s acquisition aims to leverage its commercial activation engine and product innovation strength to accelerate growth, applying its award-winning consumer-focused strategies to Kenvue’s trusted health and wellness portfolio.
Kimberly-Clark sees the acquisition of Kenvue as a means to fuse Kenvue’s science-backed and widely trusted consumer health brands with Kimberly-Clark’s market expertise to create a global health and wellness leader. The company’s mission is to combine innovation with everyday care, delivering products endorsed by healthcare professionals to meet the daily health needs of consumers at every life stage. This combination expands Kimberly-Clark’s access to billions of consumers worldwide, providing more accessible, efficient and comprehensive care solutions through an enriched product offering and enhanced innovation pipeline.
Why This Acquisition Matters
Enriched Product Offerings
The scale and resources of the combined company will boost investments in research and development, quality, and innovation capabilities, improving lives daily through the creation of innovative consumer health solutions.
Longer Lifecycle
Combining two consumer health giants, the new entity will serve consumers at every stage of life with a broader range of trusted iconic brands positioned to benefit from secular growth trends as consumers increasingly prioritize health and wellness.
Increased Upside Potential
The acquisition provides exceptional complementarity across categories, enabling the combined company to drive growth by addressing unmet consumer needs and accelerating innovation.
Geographic Expansion
Kimberly-Clark’s proven market playbook, consumer-directed innovation and social commerce expertise will be harnessed to expand in key growth geographies.
Best Of Both Worlds
Kenvue’s strong scientific foundation and relationships with healthcare professionals will be leveraged alongside Kimberly-Clark’s capabilities to enhance the combined platform’s competitive edge amongst other players in the market.
Interview Prep Questions
Associate - Investment Banking
Question: A client wants to divest a non-core division. Walk through the analysis to recommend either a spin-off or a sale to a strategic buyer, focusing on shareholder value.
You’re being tested on:
Divestiture alternatives, separation analysis, and shareholder value creation.
Core concept:
The primary analysis compares the after-tax cash proceeds from a sale (which includes potential synergies a strategic buyer might pay for) against the combined, "unlocked" market value of a standalone "SpinCo" and the remaining "RemainCo".
A critical component is quantifying the dis-synergies (e.g., loss of shared services or purchasing power) and one-time separation costs (e.g., IT, legal, rebranding), which reduce the net value to shareholders in either scenario.
Beyond the quantitative analysis, the recommendation must consider strategic factors, such as the parents' desire for an immediate cash infusion (favouring a sale) versus giving shareholders "pure-play" ownership in two distinct businesses (favouring a spin-off).
Common pitfalls.
Underestimating the complexity and cost of carving out the division's financials, including significant dis-synergies and one-time separation expenses.
Overestimating the standalone trading multiple of the "SpinCo" (which often lacks scale or a public track record) while ignoring the stranded costs and weaker profile of the "RemainCo".
Failing to accurately model the tax implications, such as the significant tax leakage from a cash sale versus the strict legal requirements for a tax-free spin-off.
Associate - M&A Deal Advisory
Question: You are leading financial due diligence on a carve-out. What are the key challenges in normalizing 'Standalone' EBITDA, and how do you address the lack of audited financials?
You’re being tested on:
Carve-out diligence, standalone cost analysis, and managing data limitations.
Core concept:
The primary goal is to recast historical financials from a "carve-out" basis (which includes arbitrary parent cost allocations) to a "standalone" basis (which reflects actual, arm's-length costs) to determine a reliable, forward-looking EBITDA.
This involves two main adjustments: removing allocated parent costs that will not continue, and adding new standalone costs the business will incur on its own (e.g., new management, IT systems, insurance).
Given the lack of audited carve-out financials, diligence must rely on substantive testing (like proof-of-cash for revenue) and a deep analysis of intercompany transactions to ensure the standalone entity is commercially viable.
Common pitfalls.
Accepting management’s standalone cost estimates without challenging the assumptions, performing independent benchmarks, or assessing the risk of cost overruns.
Ignoring the working capital impact of separation, such as the loss of favourable payment terms or pooled cash management provided by the parent company.
Failing to separate one-time, non-recurring carve-out costs (e.g., legal fees for separation, recruitment costs) from the recurring, run-rate standalone costs needed for the QoE.
Analyst - Sales & Trading
Question: A corporate client wants to hedge their floating-rate (SOFR-based) debt against rising interest rates. What product would you recommend? How does it work, and what is the primary risk left?
You’re being tested on:
Interest rate derivatives, hedging mechanics, and client risk advisory.
Core concept:
The client has floating-rate exposure (pays SOFR), which creates cash flow uncertainty if rates rise. The simplest and most liquid hedge is an Interest Rate Swap (IRS).
In this "Payer Swap," the client agrees to pay a fixed rate to the bank (locking in their cost) and receive a floating rate (SOFR) from the bank, both on an agreed-upon notional amount.
The receive-floating leg of the swap is designed to economically offset the floating-rate debt payment, leaving the client with a single, known, fixed-rate payment for the term of the hedge.
Common pitfalls
Ignoring basis risk, which occurs if the floating leg of the swap (e.g., 3-month Term SOFR) does not perfectly match the interest calculation of the debt (e.g., 1-month Compounded SOFR in Arrears).
Failing to explain the mark-to-market (MTM) and collateral implications, if rates fall, the hedge itself will become a liability and may require the client to post cash collateral.
Overlooking the counterparty credit risk of the bank, as the client is re-exposed to floating rates if the bank defaults on its obligation to pay the floating leg of the swap.
